Pulmonary Hypertension

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Pulmonary Hypertension

MalaCards integrated aliases for Pulmonary Hypertension:

Name: Pulmonary Hypertension 40 12 74 42 3 15 37 62 71
Primary Pulmonary Hypertension 40 12 74 15
Idiopathic Pulmonary Arterial Hypertension 71
Idiopathic Pulmonary Hypertension 71
Hypertension, Pulmonary 43
Hypertension Pulmonary 54


External Ids:

Disease Ontology 12 DOID:14557 DOID:6432
ICD9CM 34 416.0
MeSH 43 D006976
NCIt 49 C3120 C97119
SNOMED-CT 67 70995007
ICD10 32 I27.0 I27.20
UMLS 71 C0020542 C0152171 C3203102

Summaries for Pulmonary Hypertension

MedlinePlus : 42 Pulmonary hypertension (PH) is high blood pressure in the arteries to your lungs. It is a serious condition. If you have it, the blood vessels that carry blood from your heart to your lungs become hard and narrow. Your heart has to work harder to pump the blood through. Over time, your heart weakens and cannot do its job and you can develop heart failure. Symptoms of PH include Shortness of breath during routine activity, such as climbing two flights of stairs Tiredness Chest pain A racing heartbeat Pain on the upper right side of the abdomen Decreased appetite As PH worsens, you may find it hard to do any physical activities. There are two main kinds of PH. One runs in families or appears for no known reason. The other kind is related to another condition, usually heart or lung disease. There is no cure for PH. Treatments can control symptoms. They involve treating the heart or lung disease, medicines, oxygen, and sometimes lung transplantation. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pulmonary Hypertension, also known as primary pulmonary hypertension, is related to pulmonary hypertension, primary, 1 and chronic thromboembolic pulmonary hypertension, and has symptoms including dyspnea, edema and chest pain. An important gene associated with Pulmonary Hypertension is MIR17 (MicroRNA 17), and among its related pathways/superpathways are nNOS Signaling in Skeletal Muscle and MicroRNAs in cancer. The drugs Iloprost and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include Lung, heart and endothelial, and related phenotype is normal.

Disease Ontology : 12 A hypertension characterized by an increase of blood pressure in the pulmonary artery, pulmonary vein or pulmonary capillaries.

CDC : 3 Pulmonary hypertension occurs when the pressure in the blood vessels leading from the heart to the lungs is too high. The heart pumps blood from the right ventricle to the lungs to get oxygen. Because the blood does not have to travel very far, the pressure in this side of the heart and in the artery taking blood from the right ventricle to the lungs is normally low-normally much lower than systolic or diastolic blood pressure. When the pressure in this artery gets too high, the arteries in the lungs can narrow and then the blood does not flow as well as it should resulting in less oxygen in the blood

PubMed Health : 62 About pulmonary hypertension: Pulmonary hypertension (PULL-mun-ary HI-per-TEN-shun), or PH, is increased pressure in the pulmonary arteries. These arteries carry blood from your heart to your lungs to pick up oxygen. PH causes symptoms such as shortness of breath during routine activity (for example, climbing two flights of stairs), tiredness, chest pain, and a racing heartbeat. As the condition worsens, its symptoms may limit all physical activity.

Wikipedia : 74 Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of... more...

Related Diseases for Pulmonary Hypertension

Diseases in the Pulmonary Hypertension family:

Pulmonary Hypertension, Primary, 1 Pulmonary Hypertension, Primary, Autosomal Recessive
Pulmonary Hypertension, Primary, 2 Pulmonary Hypertension, Primary, 3
Pulmonary Hypertension, Primary, 4 Rare Pulmonary Hypertension

Diseases related to Pulmonary Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1109)
# Related Disease Score Top Affiliating Genes
1 pulmonary hypertension, primary, 1 35.8 NPPB KCNK3 EDN1 BMPR2 ACVRL1
2 chronic thromboembolic pulmonary hypertension 35.4 NPPB EDN1 BMPR2
3 pulmonary venoocclusive disease 34.3 SMAD9 PDE5A NPPB KCNK3 CAV1 BMPR2
4 heritable pulmonary arterial hypertension 34.0 SMAD9 KCNK3 CAV1 BMPR2 BMPR1B ACVRL1
5 diaphragmatic hernia, congenital 33.7 PDE5A NOS3 EDN1 BMPR2
6 eisenmenger syndrome 33.7 EDN1 BMPR2
7 persistent fetal circulation syndrome 33.6 PDE5A NOS3 EDN1
8 pulmonary valve insufficiency 33.5 PDE5A NPPB EDN1 BMPR2
9 pulmonary fibrosis, idiopathic 33.4 SMAD4 MIR21 EDN1 CAV1
10 pulmonary arterial hypertension associated with congenital heart disease 32.7 SMAD9 CAV1 BMPR2 BMPR1B
11 tricuspid valve insufficiency 32.6 PDE5A NPPB EDN1 BMPR2
12 vascular disease 32.5 NPPB NOS3 MIR21 EDN1 BMPR2 ACVRL1
13 congestive heart failure 32.4 PDE5A NPPB NOS3 EDN1
14 atrial heart septal defect 32.4 SMAD9 NPPB EDN1 BMPR2
15 heart disease 32.2 SMAD9 SMAD4 PDE5A NPPB NOS3 MIR21
16 sleep apnea 32.2 NPPB NOS3 EDN1
17 pulmonary edema 32.0 NPPB NOS3 EDN1
18 portal hypertension 32.0 NOS3 EDN1 BMPR2
19 pulmonary disease, chronic obstructive 31.9 PDE5A NPPB MIR21 MIR17
20 telangiectasis 31.9 SMAD4 BMPR2 ACVRL1
21 raynaud phenomenon 31.9 PDE5A EDN1
22 arteriovenous malformation 31.8 EDN1 BMPR2 ACVRL1
23 hereditary hemorrhagic telangiectasia 31.8 SMAD4 NOS3 BMPR2 ACVRL1
24 hepatopulmonary syndrome 31.7 NOS3 EDN1 BMPR2 ACVRL1
25 systolic heart failure 31.6 NPPB NOS3 EDN1
26 chronic mountain sickness 31.5 NPPB NOS3 EDN1
27 apnea, obstructive sleep 31.5 NPPB NOS3 EDN1
28 diastolic heart failure 31.5 PDE5A NPPB NOS3
29 connective tissue disease 31.5 MIR22 MIR21 MIR17 EDN1 BMPR2 ACVRL1
30 pulmonary embolism 31.4 TNXA PDE5A NPPB
31 impotence 31.4 PDE5A NOS3 EDN1
32 limited scleroderma 31.4 PDE5A EDN1 CAV1
33 heart valve disease 31.4 NPPB MIR21 MIR17
34 central sleep apnea 31.4 NPPB NOS3 KCNK3
35 angina pectoris 31.3 NPPB NOS3 EDN1
36 ischemia 31.3 NPPB NOS3 MIR21 EDN1 CAV1
37 chronic pulmonary heart disease 31.2 SMAD9 PDE5A NPPB NOS3 EDN1 BMPR2
38 lipoprotein quantitative trait locus 31.1 PDE5A NPPB NOS3 MIR21 EDN1
39 aortic valve disease 2 31.0 NPPB MIR21 MIR17
40 coronary heart disease 1 30.9 NPPB NOS3 MIR17 EDN1
41 renal hypertension 30.8 NPPB NOS3 EDN1
42 limb ischemia 30.7 NOS3 MIR21 EDN1
43 tricuspid valve disease 30.7 PDE5A NPPB EDN1 BMPR2
44 cardiovascular system disease 30.6 PDE5A NPPB NOS3 MIR21 MIR17 EDN1
45 nonarteritic anterior ischemic optic neuropathy 30.6 PDE5A NOS3 EDN1
46 body mass index quantitative trait locus 11 30.5 PDE5A NOS3 MIR22 MIR21 MIR17 EDN1
47 aortic disease 30.4 SMAD4 MIR21 MIR17
48 arteries, anomalies of 30.3 NOS3 MIR22 MIR21 MIR17 EDN1
49 acute myocardial infarction 30.2 NPPB MIR22 MIR21 EDN1
50 myocardial infarction 30.1 PDE5A NPPB NOS3 MIR22 MIR21 MIR17

Graphical network of the top 20 diseases related to Pulmonary Hypertension:

Diseases related to Pulmonary Hypertension

Symptoms & Phenotypes for Pulmonary Hypertension

UMLS symptoms related to Pulmonary Hypertension:

dyspnea, edema, chest pain, angina pectoris, hemoptysis, snoring, coughing

MGI Mouse Phenotypes related to Pulmonary Hypertension:

# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.28 ACVRL1 BMPR1B BMPR2 EDN1 KCNK3 NOS3

Drugs & Therapeutics for Pulmonary Hypertension

PubMed Health treatment related to Pulmonary Hypertension: 62

Pulmonary hypertension (PH) has no cure. However, treatment may help relieve symptoms and slow the progress of the disease. PH is treated with medicines, procedures, and other therapies . Treatment will depend on what type of PH you have and its severity. (For more information, go to "Types of Pulmonary Hypertension." )

Drugs for Pulmonary Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 402)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Riociguat Approved Phase 4 625115-55-1
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
Adenosine Approved, Investigational Phase 4 58-61-7 60961
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
Clevidipine Approved, Investigational Phase 4 167221-71-8
Methazolamide Approved Phase 4 554-57-4 4100
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Magnesium oxide Approved Phase 4 1309-48-4 14792
Dobutamine Approved Phase 4 34368-04-2 36811
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
Norepinephrine Approved Phase 4 51-41-2 439260
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Macitentan Approved Phase 4 441798-33-0
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
24 Coconut Approved Phase 4
Sorbitol Approved Phase 4 50-70-4 5780
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
Simendan Investigational Phase 4 131741-08-7
28 Tocotrienol Investigational Phase 4 6829-55-6
29 Angiotensin II Type 1 Receptor Blockers Phase 4
30 Angiotensinogen Phase 4
31 Angiotensin Receptor Antagonists Phase 4
32 Giapreza Phase 4
33 Vardenafil Dihydrochloride Phase 4
34 Adrenergic Agents Phase 4
35 Adrenergic beta-Agonists Phase 4
36 Adrenergic Agonists Phase 4
37 Cardiotonic Agents Phase 4
38 Phosphodiesterase 3 Inhibitors Phase 4
39 Insulin, Globin Zinc Phase 4
40 insulin Phase 4
41 Sodium Channel Blockers Phase 4
42 Cholinergic Agents Phase 4
43 Tissue Plasminogen Activator Phase 4
44 Plasminogen Phase 4
45 Bromides Phase 4
46 Cholinergic Antagonists Phase 4
47 Sympathomimetics Phase 4
48 Parasympatholytics Phase 4
49 Tiotropium Bromide Phase 4 136310-93-5
50 Thromboplastin Phase 4

Interventional clinical trials:

(show top 50) (show all 1479)
# Name Status NCT ID Phase Drugs
1 Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension Unknown status NCT01288651 Phase 4 Ferricarboxymaltose
2 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Unknown status NCT01116063 Phase 4 Inhaled iloprost
3 Hemodynamic Evaluation of Patients With Pulmonary Arterial Hypertension. Response to Sildenafil Treatment Unknown status NCT00483626 Phase 4 oral sildenafil
4 A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension Unknown status NCT02625558 Phase 4 Riociguat;Placebo
5 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
6 Raising the Bars in the Treatment of Pulmonary Arterial Hypertension: Goal Oriented Strategy to Preserve Ejection Fraction Trial Unknown status NCT03236818 Phase 4 ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
7 Effects of Spironolactone on Collagen Metabolism in Pulmonary Arterial Hypertension Unknown status NCT01468571 Phase 4 Spironolactone;Placebo
8 Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study. Unknown status NCT00637065 Phase 4 Bosentan;Placebo
9 Randomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis Unknown status NCT03053739 Phase 4 Sildenafil 20mg and Bosentan 62.5mg;Sildenafil 20mg and Placebo
10 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4 Tadalafil;Vardenafil
11 Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism: AYKAN Trial Unknown status NCT02029456 Phase 4 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
12 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
13 Comparative Effect of Combined High Spinal and General Anaesthesia With General Anaesthesia Alone On Right Ventricular Function In Patients With Mitral Valvular Disease With Pulmonary Hypertension Unknown status NCT03013075 Phase 4 Bupivacaine heavy and Morphine;General Anesthetics
14 Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost Unknown status NCT01649739 Phase 4 Levitra
15 The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease Unknown status NCT01138254 Phase 4
16 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
17 Open Label, Non Comparative Study to Investigate the Effect of Bosentan on Pulmonary Artery Remodelling in Pulmonary Arterial Hypertension (PAH). Completed NCT00595049 Phase 4 bosentan
18 Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension Completed NCT00004754 Phase 4 epoprostenol
19 An Open-label Extension of Study AC-066A401 Investigating the Safety and Tolerability of ACT-385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) Completed NCT01105117 Phase 4 ACT-385781A (Actelion Epoprostenol);Flolan®
20 A Phase IV, Open-label, Randomized, Multicenter Study of the Safety, Tolerability,and Pharmacokinetics of ACT- 385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) Completed NCT01105091 Phase 4 ACT-385781A (Actelion Epoprostenol);Flolan®
21 An Open Label, Multi-center Study Evaluating the Safety of Long-term Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis® (Iloprost) in Subjects With Pulmonary Arterial Hypertension. Completed NCT00741819 Phase 4 Inhaled treprostinil
22 A Randomized, Placebo Controlled, Single Center Clinical Trial for Evaluation of Efficacy and Safety of Sildenafil Administration in the Cardiac ICU Following Mitral Valve Surgery in Patients With Pulmonary Hypertension Completed NCT02378649 Phase 4 Sildenafil;Placebo
23 Randomised Cross-over Pilot Study to Determine the Effects of Isoflurane and Propofol on Pulmonary Vascular Resistance in Children With Pulmonary Hypertension. Completed NCT01212523 Phase 4 propofol and isoflurane
24 Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study Completed NCT00303459 Phase 4 bosentan;placebo
25 A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension Completed NCT01642407 Phase 4 Sildenafil
26 A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjects With Pulmonary Hypertension With and Without Right Ventricular Dysfunction Completed NCT01839110 Phase 4 Ranolazine;Placebo
27 Echo Study - Characterization of LV Strain Patterns in Patients With Mildly Elevated PCWP and Pulmonary Hypertension Completed NCT01800292 Phase 4 sildenafil
28 Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00403650 Phase 4 Iloprost
29 A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Using Cardiovascular MRI Completed NCT02829034 Phase 4 Ranolazine;Placebo
30 COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-Minute Walk Test (6-MWT) Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of Magnetic Resonance Imaging (MRI) on Cardiac Remodeling Completed NCT00433329 Phase 4 Bosentan;Sildenafil
31 TRACLEER® (Bosentan) Pulmonary Arterial Hypertension A Multicenter, Open-label, Single-arm Safety Study to Investigate the Effects of Chronic TRACLEER® Treatment on Testicular Function in Male Patients With Pulmonary Arterial Hypertension Completed NCT00082186 Phase 4 bosentan
32 Vasoreactivity Testing With Intravenous Sildenafil in Patients With Precapillary Pulmonary Hypertension (Treatment Optimisation Study) Completed NCT01889966 Phase 4 Sildenafil
33 A Phase IV, Prospective, Single-Arm, Open-Label Study to Measure Outcomes in Patients With Pulmonary Arterial Hypertension Not on Active Treatment Completed NCT02191137 Phase 4 Riociguat (Adempas, BAY63-2521)
34 Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Pulmonary Arterial Hypertension Children Associated With Left to Right Shunt Congenital Heart Defect Completed NCT03431649 Phase 4 Beraprost Sodium;Sildenafil Citrate
35 Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension Completed NCT01330108 Phase 4 ambrisentan
36 Therapy of Pulmonary Arterial Hypertension (PAH) With Bosentan in Patients With Eisenmenger Syndrome Completed NCT00266162 Phase 4 Bosentan administration
37 The Effect of Riociguat on Gas Exchange, Exercise Performance, and Pulmonary Artery Pressure During Acute Altitude Exposure Completed NCT02024386 Phase 4 Riociguat
38 Acute Effect of Recombinant Human Brain Natriuretic Peptide in Patients With Pulmonary Hypertension Associated With Acute Exacerbation of Chronic Pulmonary Disease Completed NCT02742909 Phase 4 rhBNP;placebo
39 Sildenafil for Improving Outcomes After Valvular Correction Completed NCT00862043 Phase 4 Sildenafil Citrate;Placebo
40 Phase IV Study on the Effects of Sildenafil in Combination With Pulmonary Rehabilitation Program on Exercise Tolerance in Patients With COPD and Pulmonary Hypertension Completed NCT01055405 Phase 4 Sildenafil
41 Natrecor® (Nesiritide) as a Nitric Oxide Sparing Agent in Patients Undergoing Lung Transplantation Completed NCT00205426 Phase 4 Natrecor
42 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis Completed NCT01042158 Phase 4 tadalafil and ambrisentan upfront combination therapy
43 A Multicenter, Randomized, Parallel Placebo-Controlled Study of the Safety and Efficacy of Subcutaneous Remodulin® Therapy After Transition From Flolan® in Patients With Pulmonary Arterial Hypertension Completed NCT00058929 Phase 4 treprostinil sodium
44 CombinatiON Up-FRON t Therapy for PAH - A Phase 4, Randomized, Multicenter Study of Inhaled Treprostinil in Treatment naïve Pulmonary Arterial Hypertension Patients Starting on Tadalafil Completed NCT01305252 Phase 4 treprostinil inhalations;tadalafil
45 Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study Completed NCT01051960 Phase 4 Ambrisentan
46 Acute Effects of a Single Dose of Sildenafil (20mg/40mg) on Pulmonary Haemodynamics and Gas Exchange at Rest and During Exercise in COPD Patients With Pulmonary Hypertension Completed NCT00491803 Phase 4 Sildenafil;Sildenafil
47 Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) in Patients With Stable Pulmonary Arterial Hypertension: Safety, Efficacy and Treatment Satisfaction Completed NCT00373360 Phase 4 treprostinil sodium
48 Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE) Completed NCT01121458 Phase 4 Clevidipine
49 Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns: A Randomized Placebo Controlled Trial Completed NCT01757782 Phase 4 Oral Sildenafil;Placebo (distilled water)
50 A Phase 4, Placebo Controlled, Single-blind, Cross-over Safety Study to Evaluate the Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR) as Measured by Right Heart Catheterization Completed NCT00878878 Phase 4 Optison (Perflutren Protein-Type A Microspheres Injectable Suspension);Dextrose

Search NIH Clinical Center for Pulmonary Hypertension

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Epoprostenol Sodium
Hydralazine Hydrochloride

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pulmonary Hypertension cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: hypertension, pulmonary

Genetic Tests for Pulmonary Hypertension

Anatomical Context for Pulmonary Hypertension

MalaCards organs/tissues related to Pulmonary Hypertension:

Heart, Lung, Endothelial, Smooth Muscle, Testes, Liver, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pulmonary Hypertension:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Pulmonary Capillary Plexus Affected by disease

Publications for Pulmonary Hypertension

Articles related to Pulmonary Hypertension:

(show top 50) (show all 30269)
# Title Authors PMID Year
Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. 46 54 61
19390056 2009
Pulmonary Vascular Disease Evaluation with Magnetic Resonance Angiography. 42 61
32471539 2020
Prognostic impact of red blood cell distribution width in pulmonary hypertension patients: A systematic review and meta-analysis. 61 42
32311918 2020
Susceptibility to chronic thromboembolic pulmonary hypertension may be conferred by miR-759 via its targeted interaction with polymorphic fibrinogen alpha gene. 46 61
20677013 2010
Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. 61 46
20110569 2010
Potential mechanisms and serum biomarkers involved in sex differences in pulmonary arterial hypertension. 42
32221085 2020
Transcripts from a novel BMPR2 termination mutation escape nonsense mediated decay by downstream translation re-initiation: implications for treating pulmonary hypertension. 61 54
20095988 2010
Placenta growth factor in sickle cell disease: association with hemolysis and inflammation. 54 61
20040765 2010
Emerging therapies for the treatment of pulmonary hypertension. 61 54
20216170 2010
B-type natriuretic peptide utilization as an adjunct to management in a case of conjoined twins with pulmonary hypertension. 61 54
20085871 2010
Genetic polymorphisms of the serotonin transporter, but not the 2a receptor or nitric oxide synthetase, are associated with pulmonary hypertension in chronic obstructive pulmonary disease. 54 61
19556740 2010
Pulmonary hemodynamic response to acute combination and monotherapy with sildenafil and brain natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension. 61 54
19996941 2010
Phosphodiesterase type 5 inhibitors for high-altitude pulmonary hypertension: a meta-analysis. 54 61
20225909 2010
Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to clinical parameters and comparison with left heart disease. 54 61
19844076 2010
Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. 61 54
19679640 2009
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. 61 54
20054445 2009
Interaction between bone morphogenetic proteins and endothelin-1 in human pulmonary artery smooth muscle. 61 54
19786120 2009
Nitric oxide synthases in infants and children with pulmonary hypertension and congenital heart disease. 54 61
19912632 2009
Brain natriuretic peptide in chronic thromboembolic pulmonary hypertension. 61 54
19468826 2009
Expression of vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets. 61 54
19581838 2009
A novel insight into the mechanism of pulmonary hypertension involving caveolin-1 deficiency and endothelial nitric oxide synthase activation. 54 61
20382348 2009
Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor. 61 54
19592462 2009
Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion. 54 61
19659904 2009
Endothelin-1 across the lung circulation in patients with pulmonary arterial hypertension and influence of epoprostenol infusion. 54 61
19632577 2009
Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary hypertension in rats. 54 61
19337232 2009
Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats. 54 61
19386793 2009
Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. 61 54
19487814 2009
Right atrium contractility and right ventricular diastolic function assessed by pulsed tissue Doppler imaging can predict brain natriuretic peptide in adults with acquired pulmonary hypertension. 61 54
18793807 2009
RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. 61 54
19299501 2009
Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. 61 54
18599134 2009
Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signalling in pulmonary artery smooth muscles cells. 61 54
19416631 2009
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. 54 61
19263460 2009
Plasma endothelin-1 and nitrate levels in Down's syndrome with complete atrioventricular septal defect-associated pulmonary hypertension: a comparison with non-Down's syndrome children. 61 54
18682983 2009
Caveolin-1 Expression and Hemodynamics in COPD Patients. 54 61
19572028 2009
Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 54 61
19377497 2009
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 54 61
19247590 2009
Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. 61 54
19121410 2009
Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. 61 54
19181291 2009
Hypoxic upregulation of preproendothelin-1 gene expression is associated with protein tyrosine kinase-PI3K signaling in cultured lung vascular endothelial cells. 61 54
19436835 2009
NO-independent, haem-dependent soluble guanylate cyclase stimulators. 61 54
19089334 2009
[Estimation of plasmic concentration of the brain natriuretic peptide in interstitial pulmonary diseases with pulmonary hypertension: clinical role]. 54 61
19459423 2009
Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer. 54 61
19544975 2009
Role of nitric oxide in shock: the large animal perspective. 61 54
19273179 2009
[Endothelin-1 and brain natriuretic peptide in the development of pulmonary hypertension in interstitial lung diseases]. 54 61
20481052 2009
Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension. 54 61
18790993 2008
Differential roles of endothelin-1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lung. 61 54
18567602 2008
Inhalation of vasoactive intestinal peptide in pulmonary hypertension. 61 54
18978135 2008
["Pulmonary hypertension" of the gastrointestinal tract in patients with systemic sclerosis: thoughts on a not (yet) existing disease entity]. 61 54
18814097 2008
Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. 61 54
18552156 2008
Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells. 54 61
18539760 2008

Variations for Pulmonary Hypertension

Expression for Pulmonary Hypertension

Search GEO for disease gene expression data for Pulmonary Hypertension.

Pathways for Pulmonary Hypertension

Pathways related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
Show member pathways
2 12.32 MIR451A MIR21 MIR20A MIR17 BMPR2
Show member pathways
5 11.7 SMAD4 NOS3 EDN1
7 11.67 SMAD9 SMAD4 ACVRL1
Show member pathways
Show member pathways
11 10.61 PDE5A NOS3
12 10.47 SMAD9 SMAD4 BMPR2

GO Terms for Pulmonary Hypertension

Cellular components related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 NPPB MIR451A MIR22 MIR21 MIR20A MIR17
2 caveola GO:0005901 9.33 NOS3 CAV1 BMPR2
3 extracellular vesicle GO:1903561 9.02 MIR451A MIR22 MIR21 MIR20A MIR17
4 SMAD protein complex GO:0071141 8.96 SMAD9 SMAD4

Biological processes related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 10.11 MIR451A MIR22 MIR21 MIR20A MIR17
2 negative regulation of cell proliferation GO:0008285 10.06 SMAD4 NOS3 MIR21 CAV1 ACVRL1
3 in utero embryonic development GO:0001701 9.99 SMAD4 NOS3 EDN1 ACVRL1
4 response to hypoxia GO:0001666 9.92 SMAD4 EDN1 CAV1 ACVRL1
5 positive regulation of angiogenesis GO:0045766 9.91 NOS3 MIR21 MIR20A ACVRL1
6 miRNA mediated inhibition of translation GO:0035278 9.89 MIR21 MIR20A MIR17
7 negative regulation of gene expression GO:0010629 9.88 MIR451A MIR21 MIR20A MIR17 EDN1 ACVRL1
8 cellular response to growth factor stimulus GO:0071363 9.86 BMPR2 BMPR1B ACVRL1
9 negative regulation of cell growth GO:0030308 9.85 SMAD4 NPPB BMPR2 ACVRL1
10 positive regulation of osteoblast differentiation GO:0045669 9.83 MIR21 BMPR2 BMPR1B
11 cellular response to transforming growth factor beta stimulus GO:0071560 9.82 EDN1 CAV1 ACVRL1
12 positive regulation of endothelial cell migration GO:0010595 9.81 MIR21 EDN1 BMPR2
13 outflow tract morphogenesis GO:0003151 9.81 MIR20A MIR17 BMPR2
14 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.79 SMAD4 BMPR2 ACVRL1
15 dorsal/ventral pattern formation GO:0009953 9.77 EDN1 BMPR1B ACVRL1
16 ventricular septum morphogenesis GO:0060412 9.75 SMAD4 NOS3 BMPR2
17 positive regulation of BMP signaling pathway GO:0030513 9.74 SMAD4 BMPR2 ACVRL1
18 regulation of blood pressure GO:0008217 9.73 NPPB NOS3 EDN1 ACVRL1
19 positive regulation of endothelial cell differentiation GO:0045603 9.72 MIR21 ACVRL1
20 endocardial cushion morphogenesis GO:0003203 9.72 NOS3 ACVRL1
21 positive regulation of cartilage development GO:0061036 9.71 BMPR2 BMPR1B
22 vasoconstriction GO:0042310 9.71 EDN1 CAV1
23 negative regulation of DNA biosynthetic process GO:2000279 9.71 BMPR2 ACVRL1
24 blood vessel remodeling GO:0001974 9.71 NOS3 BMPR2 ACVRL1
25 positive regulation of renal sodium excretion GO:0035815 9.7 NPPB EDN1
26 positive regulation of urine volume GO:0035810 9.7 NPPB EDN1
27 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.7 MIR21 CAV1
28 lymphangiogenesis GO:0001946 9.7 BMPR2 ACVRL1
29 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.69 MIR20A MIR17
30 response to transforming growth factor beta GO:0071559 9.69 SMAD4 EDN1
31 response to dexamethasone GO:0071548 9.69 EDN1 CPS1
32 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.69 MIR451A MIR21 MIR20A
33 positive regulation of metalloendopeptidase activity GO:1904685 9.68 MIR21 MIR17
34 artery development GO:0060840 9.68 BMPR2 ACVRL1
35 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.67 MIR21 EDN1
36 body fluid secretion GO:0007589 9.67 NPPB EDN1
37 positive regulation of cardiac muscle hypertrophy GO:0010613 9.67 PDE5A MIR21 EDN1
38 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 MIR21 MIR20A MIR17 EDN1
39 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.66 SMAD9 SMAD4
40 retina vasculature development in camera-type eye GO:0061298 9.66 BMPR2 ACVRL1
41 endothelial tube morphogenesis GO:0061154 9.65 MIR21 ACVRL1
42 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0007178 9.65 BMPR2 BMPR1B ACVRL1
43 transforming growth factor beta receptor signaling pathway GO:0007179 9.65 SMAD9 SMAD4 MIR21 BMPR2 ACVRL1
44 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.64 MIR21 MIR17
45 lymphatic endothelial cell differentiation GO:0060836 9.63 BMPR2 ACVRL1
46 negative regulation of systemic arterial blood pressure GO:0003085 9.63 NPPB MIR17 BMPR2
47 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.62 NOS3 EDN1
48 negative regulation of endothelial cell proliferation GO:0001937 9.62 MIR22 MIR21 CAV1 ACVRL1
49 venous blood vessel development GO:0060841 9.59 BMPR2 ACVRL1
50 endochondral bone morphogenesis GO:0060350 9.58 BMPR2 BMPR1B

Molecular functions related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.62 MIR22 MIR21 MIR20A MIR17
2 transforming growth factor beta-activated receptor activity GO:0005024 9.26 BMPR2 ACVRL1
3 BMP receptor activity GO:0098821 9.16 BMPR2 ACVRL1
4 transforming growth factor beta receptor activity, type I GO:0005025 8.96 BMPR1B ACVRL1
5 transmembrane receptor protein serine/threonine kinase activity GO:0004675 8.8 BMPR2 BMPR1B ACVRL1

Sources for Pulmonary Hypertension

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....